Danazol therapy in idiopathic thrombocytopenic purpura: the efficacy of low-medium dose therapy.

Abstract

To examine the effects and optimal dose of danazol on idiopathic thrombocytopenic purpura (ITP), we administered a low-medium dose to 14 patients with this disease. A low-medium dose of danazol was effective in maintaining the platelet count at a high level, even after the dose of prednisolone was reduced. A low-medium dose of danazol without other therapy was effective in 3 of 6 patients even after they had been refractory to other treatment. A low dose of danazol was also effective in some patients for whom the other regimes were not indicated. It is concluded that a low-medium dose of danazol instead of a high dose is worth trying in ITP when the patient has become refractory to other therapeutic approaches or when these are not indicated.

• Authors: H Kondo, T Iseki, S Goto, T Takaso, M Ohto, K Okuda
• Journal: International journal of hematology (Int J Hematol) Vol. 55 Issue 3 Pg. 293-300 (Jun 1992) ISSN: 0925-5710 [Print] Japan
• PMID: 1498320 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Autoantibodies
• Immunoglobulin G
• Prednisolone
• Danazol

Topics

• Adult
• Aged
• Autoantibodies (immunology)
• Autoimmune Diseases (drug therapy, surgery, therapy)
• Blood Platelets (immunology)
• Combined Modality Therapy
• Danazol (administration & dosage, therapeutic use)
• Female
• Humans
• Immunoglobulin G (blood)
• Immunosuppression Therapy
• Male
• Middle Aged
• Platelet Count (drug effects)
• Prednisolone (therapeutic use)
• Purpura, Thrombocytopenic, Idiopathic (drug therapy, surgery, therapy)
• Splenectomy
• Treatment Outcome